

SESSION OF 2014

**SUPPLEMENTAL NOTE ON SENATE SUBSTITUTE FOR
HOUSE BILL NO. 2298**

As Recommended by Senate Committee on
Judiciary

Brief*

Senate Sub. for HB 2298 would amend the statutes governing controlled substances to add several additional drugs or drug classes to the schedules of controlled substances.

Specifically, the bill would add 14 hallucinogenic drugs, two classes of cannabinoids, and a cannabinoid class name to schedule I; two anabolic steroids to schedule III; and lorcaserin to schedule IV.

Background

As introduced by the 2013 House Committee on Corrections and Juvenile Justice and passed by the House in 2013, HB 2298 would have amended the penalty for the crime of giving a false alarm.

The 2014 Senate Committee on Judiciary placed the original contents of HB 2298 into Senate Sub. for HB 2655. The Committee deleted the contents of HB 2298 and recommended a substitute bill containing the contents of SB 437, amending the Uniform Controlled Substances Act.

*Supplemental notes are prepared by the Legislative Research Department and do not express legislative intent. The supplemental note and fiscal note for this bill may be accessed on the Internet at <http://www.kslegislature.org>

Background of SB 437

SB 437 was introduced by the Senate Committee on Federal and State Affairs. In the Senate Committee on Judiciary, a Kansas Bureau of Investigation forensic scientist testified in support of the bill, stating it would bring the Kansas drug schedules in line with federal law and address other drugs that have appeared in Kansas. Written testimony supporting the bill was received from representatives of the Johnson County Sheriff's Office, the Kansas Board of Pharmacy, and the Kansas County and District Attorneys Association. There was no neutral or opponent testimony.

According to the fiscal note prepared by the Division of the Budget on SB 437, the Kansas Sentencing Commission indicates the bill could result in additional prison admissions and add to the workload of the Commission, but there is no data available regarding the drugs listed in the bill upon which to base an impact estimate.